These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

484 related items for PubMed ID: 16545206

  • 1. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review.
    Connock M, Frew E, Evans BW, Bryan S, Cummins C, Fry-Smith A, Li Wan Po A, Sandercock J.
    Health Technol Assess; 2006 Mar; 10(7):iii, ix-118. PubMed ID: 16545206
    [Abstract] [Full Text] [Related]

  • 2. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.
    Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C.
    Health Technol Assess; 2005 Apr; 9(15):1-157, iii-iv. PubMed ID: 15842952
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.
    Health Technol Assess; 2001 Apr; 5(28):1-110. PubMed ID: 11701100
    [Abstract] [Full Text] [Related]

  • 7. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.
    Dündar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, Bogg J, Dickson R, Walley T.
    Health Technol Assess; 2004 Jun; 8(24):iii-x, 1-125. PubMed ID: 15193209
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C, Burch J, Suekarran S, Walker S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Lorgelly P, Fenwick L, Palmer S.
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [Abstract] [Full Text] [Related]

  • 10. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II).
    Balabanova S, Taylor C, Sills G, Burnside G, Plumpton C, Smith PEM, Appleton R, Leach JP, Johnson M, Baker G, Pirmohamed M, Hughes DA, Williamson PR, Tudur-Smith C, Marson AG.
    BMJ Open; 2020 Aug 26; 10(8):e040635. PubMed ID: 32847927
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The cost-effectiveness of newer drugs as add-on therapy for children with focal epilepsies.
    Frew EJ, Sandercock J, Whitehouse WP, Bryan S.
    Seizure; 2007 Mar 26; 16(2):99-112. PubMed ID: 17161630
    [Abstract] [Full Text] [Related]

  • 16. Newer antiepileptic drugs. Towards an improved risk-benefit ratio.
    Patsalos PN, Sander JW.
    Drug Saf; 1994 Jul 26; 11(1):37-67. PubMed ID: 7917080
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J, Cooper K, Harris P, Picot J, Rose M.
    Health Technol Assess; 2016 Apr 26; 20(34):1-222. PubMed ID: 27135404
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.